Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
US-9216970-B2 · Dec 22, 2015 · US
Bicyclic thiazole compounds
US9102637B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9102637-B2 |
| Application number | US-201314403071-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 22, 2013 |
| Priority date | May 24, 2012 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R 1 , R 2 , R 3 and Q are as defined in the specification), or a pharmaceutically acceptable salt thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound represented by the following general formula: (wherein, R 1 is wherein each of A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 is, independently C—Z or N, R 2 is a hydrogen atom, a substituted or unsubstituted a…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
- C07D277/56Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
- C07D417/12Primary
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9102637B2 cover?
- The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next for…
- Who is the assignee on this patent?
- Carna Biosciences Inc, Nat Cancer Ct, Carna Biosciences Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D277/56. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).